**HERMANOWICZ, Kamil, OLEKSY, Daria, DOMAN, Katarzyna, NOWAK, Julia, CIOCH, Michał Jakub, NAJDEK, Agnieszka, KOMADA, Dawid, KACZMARSKA, Urszula, WOŹNIAK, Aleksandra and MYCYK, Marcin. Therapeutic Potential of 1,8-Cineole in Respiratory Diseases with a Focus on Asthma, Sinusitis, and Upper Respiratory Tract Infections: A Comprehensive Review. Journal of Education, Health and Sport. 2025;78:57692. eISSN 2391-8306.**
**https://doi.org/10.12775/JEHS.2025.78.57692**
**https://apcz.umk.pl/JEHS/article/view/57692**

The journal has had 40 points in Minister of Science and Higher Education of Poland parametric evaluation. Annex to the announcement of the Minister of Education and Science of 05.01.2024 No. 32318. Has a Journal's Unique Identifier: 201159. Scientific disciplines assigned: Physical culture sciences (Field of medical and health sciences); Health Sciences (Field of medical and health sciences).
Punkty Ministerialne 40 punktów. Załącznik do komunikatu Ministra Nauki i Szkolnictwa Wyższego z dnia 05.01.2024 Lp. 32318. Posiada Unikatowy Identyfikator Czasopisma: 201159. Przypisane dyscypliny naukowe: Nauki o kulturze fizycznej (Dziedzina nauk medycznych i nauk o zdrowiu); Nauki o zdrowiu (Dziedzina nauk medycznych i nauk o zdrowiu).
The authors declare that there is no conflict of interests regarding the publication of this paper.
Received: 09.01.2025. Revised: 28.01.2025. Accepted: 06.02.2025. Published: 12.02.2025.

# Therapeutic Potential of 1,8-Cineole in Respiratory Diseases with a Focus on Asthma, Sinusitis, and Upper Respiratory Tract Infections: A Comprehensive Review

**Kamil Hermanowicz** [KH]
SPZOZ w Zelowie, Żeromskiego 21, 97-425 Zelów, Poland
ORCID: https://orcid.org/0009-0007-0844-1424
e-mail: Kamil03h8@gmail.com

**Daria Oleksy** [DO]
Przychodnia Zespołu Lekarzy Rodzinnych LEKMED s.c. Czerwonego Krzyża 2, 63-000 Środa Wielkopolska, Poland
ORCID: https://orcid.org/0009-0004-4492-3752
e-mail: daria.oleksy.1996@gmail.com

**Katarzyna Doman** [KD]
NZOZ MEDICUS ,ul. Opiesińska 10-12, 98-220 Zduńska Wola, Poland
ORCID: https://orcid.org/0009-0005-1022-490X
e-mail: kadomanka@gmail.com

**Julia Nowak** [JN]
RAW-MEDICA NZOZ, Słowackiego 68, 96-200 Rawa Mazowiecka, Poland
ORCID: https://orcid.org/0009-0009-5954-8138
e-mail: jwilkusz@gmail.com

**Michał Jakub Cioch** [MJC]
Centrum Medyczne LUX MED al. Pokoju 18c, 31-564 Kraków, Poland
ORCID: https://orcid.org/0009-0007-1555-3336
e-mail: michalcioch1@gmail.com

**Agnieszka Najdek** [AN]
Teaching Hospital No. 2 of the Medical University of Lodz, Żeromskiego Street 113 90-549 Lodz, Poland
ORCID: https://orcid.org/0009-0000-1112-3864
e-mail: agnieszka.najdek99@gmail.com

**Dawid Komada** [DK]
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie, ul. Złotej Jesieni 1, 31-826 Kraków, Poland
ORCID: https://orcid.org/0009-0009-6015-8292
e-mail: komada.dawid.lek@gmail.com

**Urszula Kaczmarska** [UK]
ZOZ Ropczyce 39-100 Ropczyce, ul. Ks. Kard. St. Wyszyńskiego 54, Poland
ORCID https://orcid.org/0009-0007-2986-5760
e-mail: urszulakaczmarskaa@gmail.com

**Aleksandra Woźniak** [AW]
Faculty of Medicine, Medical University of Lodz, al. Tadeusza Kościuszki 4, 90-419, Łódź, Poland
ORCID: https://orcid.org/0009-0004-7769-9865
e-mail: aleksandra.wozniak4@stud.umed.lodz.pl

**Marcin Mycyk** [MM]
Piotr Pelcer Klinika Zdrowia Sp. z o.o. Filia Kębłowo, ul. Chłopska 13, 84-242 Kębłowo, Poland
ORCID: https://orcid.org/0009-0001-2553-3327
E-mail: marcinmycyk@gmail.com

Corresponding author:
Kamil Hermanowicz [KH]
SPZOZ w Zelowie, Żeromskiego 21, 97-425 Zelów, Poland
ORCID: https://orcid.org/0009-0007-0844-1424
e-mail: Kamil03h8@gmail.com

## Abstract

### Introduction

Respiratory diseases, such as chronic sinusitis, asthma, and URTIs, are among the leading global health burdens, affecting tens of millions of people every year. These conditions often involve chronic inflammation, impaired mucociliary function, and obstruction of the airways, leading to deteriorating respiratory health. Classic pharmacological treatments, involving corticosteroids and bronchodilators, focus on symptom alleviation but are commonly linked with a variety of side effects and deficiencies in adequately targeting the disease mechanisms.

The natural compound 1,8-cineole is a monoterpene present in eucalyptus oil and has received attention in recent times as an alternative therapeutic agent for respiratory diseases. Its anti-inflammatory, antioxidant, mucolytic, bronchodilatory, antiviral, and antimicrobial effects may be beneficial in the management of these diseases. Clinical evidence has shown that 1,8-cineole provides symptom relief, improves lung function, and enhances quality of life,

particularly in patients with COPD, asthma, and chronic sinusitis. Besides, due to its good safety profile and minimal side effects, it represents a very attractive adjunctive treatment option.

The mechanisms of action and clinical applications of 1,8-cineole in respiratory diseases were examined, with the emphasis on the effects of this substance against inflammation, infection, and airway remodeling. The current evidence has been summarized herein, underlining the potential for 1,8-cineole to serve as a natural, multifunctional agent in respiratory therapeutics.

1,8-Cineole represents a promising alternative or Methods
This review synthesizes both classic and contemporary research findings on the mechanisms of action, clinical efficacy, and safety profile of 1,8-cineole. A comprehensive literature search was conducted across peer-reviewed journals to provide a balanced and evidence-based overview.

**Results**
Evidence indicates that 1,8-cineole effectively modulates inflammatory pathways by inhibiting cytokine release and suppressing arachidonic acid metabolism. Clinical trials demonstrate its efficacy in reducing symptoms of chronic sinusitis, improving pulmonary function in asthma, and alleviating symptoms in URTIs. Safety data support its tolerability, with mild gastrointestinal discomfort reported in rare cases.

**Conclusion**
adjunctive treatment for inflammatory respiratory conditions. Future research should focus on optimizing delivery methods and investigating its synergistic potential with existing therapies.

**Keywords:** 1,8-Cineole; respiratory diseases; chronic sinusitis; asthma; URTIs; anti-inflammatory; mucolytic therapy; immunomodulation.

## Introduction

Respiratory diseases represent a significant global health burden, affecting millions annually. Among these, chronic sinusitis, asthma, and URTIs are characterized by inflammation and impaired respiratory function. Traditional pharmacological treatments, such as corticosteroids and bronchodilators, provide symptom relief but are often associated with adverse effects. Eucalyptol therapy markedly improved breathing difficulties, lung function, and overall quality of life compared to a placebo in patients with stable COPD. [1] The natural compound 1,8-cineole offers an alternative therapeutic approach, with evidence supporting its diverse biological properties, such as anti-inflammatory, antioxidant, free radical scavenging, mucolytic/secretolytic, bronchodilatory, antiviral, and antimicrobial effects, as highlighted in other reviews. [2] This review explores the impact of 1,8-cineole on these conditions, emphasizing its mechanisms of action and clinical applications.

## Mechanisms of Action of 1,8-Cineole

### Anti-Inflammatory Properties

1,8-Cineole modulates key inflammatory pathways by inhibiting the release of pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6). [3] It also suppresses the arachidonic acid cascade, reducing prostaglandin and leukotriene production, as demonstrated in clinical and in vitro studies. [4] [5] Furthermore, it downregulates cyclooxygenase-2 (COX-2) and 5-lipoxygenase pathways, leading to decreased inflammatory mediator levels. [1]

### Mucolytic and Symptom Relief Properties

Cineole's mucolytic properties stem from its ability to enhance ciliary beat frequency and reduce mucus viscosity, promoting efficient mucus clearance from the respiratory tract. [6] Clinical trials have reported that patients with URTIs treated with cineole experience faster symptom resolution, including reduced nasal discharge and improved airflow.

The impact of 1,8-cineole on regulating mucus hypersecretion was investigated using an ex vivo model of experimental rhinosinusitis in lipopolysaccharide (LPS)-stimulated nasal slice

cultures. For the first time, the study demonstrated a significant reduction in mucin-filled goblet cells and decreased expression of mucin genes MUC2 and MUC19, accompanied by notably reduced activity of the nuclear factor kappa B (NF-κB) pathway. [7]

**Immunomodulation**

The compound also exerts immunomodulatory effects by regulating Th1/Th2 balance and reducing oxidative stress within the respiratory epithelium. [8] Recent research highlights its ability to enhance interferon regulatory factor 3 (IRF3) activity, providing an antiviral edge in managing respiratory infections. [**9]**

**Antiviral Activity**

Studies reveal the antiviral capabilities of 1,8-cineole, particularly in addressing rhinoviruses and coronaviruses, key contributors to the common cold. [10] This prevalent condition affects adults' multiple times annually and arises mainly from respiratory infections caused by these viruses, with influenza playing a secondary role. Typical manifestations, including sneezing, sore throat, coughing, and fatigue, underline the potential of 1,8-cineole as an effective natural agent for mitigating symptoms and combating viral infections. [11]

The antiviral mechanism of 1,8-cineole involves its ability to modulate key signaling pathways in response to viral infections. First 1,8-cineole significantly enhances IRF3 activity, a critical transcription factor in antiviral responses. This activation leads to the expression of antiviral cytokines such as IFN-β and RANTES, which help mediate the immune response to ssRNA viruses like rhinoviruses. [10] Secondarily, while boosting IRF3 activity, 1,8-cineole concurrently suppresses NF-κB signaling, reducing the production of pro-inflammatory cytokines like TNFα. This dual action limits excessive inflammation, which is a hallmark of severe respiratory infections and associated complications. [12] What is more, 1,8-cineole has been shown to directly inactivate free viral particles, as observed with other terpenoids against viruses like HSV-1. [13]. Finally, in models simulating bacterial co-infections, 1,8-cineole enhances IRF3 nuclear translocation and increases the expression of antiviral genes, further emphasizing its therapeutic potential during complex infections such as rhinosinusitis. [10]

**Antimicrobial Activity**

Previous research exploring the synergistic effects of essential oils, such as cineole, combined with antimicrobial agents like chlorhexidine, suggests that their enhanced activity may result from targeting either distinct or overlapping sites on bacterial cells. [14][15]. The studies assessed the antimicrobial properties of chlorhexidine (CHG) in combination with 1,8-cineole against a range of pathogens, including S. aureus, MRSA, E. coli, K. pneumoniae, E. faecalis, P. aeruginosa, and C. albicans.This synergy suggests that combining CHG with 1,8-cineole may provide an effective strategy for improving antimicrobial treatments, aligning with prior research that underscores the antimicrobial potential of both compounds. [16] [17] Biofilm formation significantly hinders the effectiveness of antimicrobial treatments due to its low permeability. However, 1,8-cineole has demonstrated the ability to penetrate E. coli biofilm, with its efficacy potentially increasing under conditions of osmotic stress. [18]

Recent studies demonstrated that essential oils derived from Eucalyptus globulus, with 1,8-cineole comprising the majority of its metabolites (65.83%), exhibited antimicrobial activity against Streptococcus mutans, including in biofilm cultures mimicking dental plaque conditions. [19] Studies on the pathogenic S. aureus, the predominant bacterial species in chronic rhinosinusitis, revealed that 1,8-cineole not only inhibits bacterial growth but also plays a critical role in suppressing proteins specifically associated with biofilm formation, highlighting its importance in combating biofilm-related infections. [20]

**Safety and Tolerability**

Clinical data support the safety of 1,8-cineole, with mild adverse effects such as gastrointestinal discomfort reported in rare cases. The MDPI study specifically highlights mild gastric distress such as nausea or diarrhea was described as a potential side effect in a few patients in a bronchial asthma study. [21] Contraindications include use in infants, children under the age of 5 and also individuals with hypersensitivity to eucalyptus oil. [22][23] However, its tolerability profile is highly favorable compared to traditional pharmacological treatments. Long-term studies confirm the absence of significant toxicological risks, making it suitable for prolonged use in chronic conditions.

**Clinical Applications**

**Upper Respiratory Tract Infections (URTIs)**

The common etiology of URTIs involves viral pathogens that cause inflammation and congestion of the upper respiratory tract. A growing body of evidence has pointed toward the therapeutic role of 1,8-cineole in URTIs due to its unique combination of antiviral, anti-inflammatory, and mucolytic properties. It is this property that enables this compound to act effectively against the root causes of URTI and its symptoms.

A randomized, double-blind, placebo-controlled study evaluated the efficacy of 1,8-cineole in patients with acute non-purulent rhinosinusitis. Participants received two 100 mg capsules of cineole three times daily for 7 days. The study found a significant reduction in mean symptom scores after both 4 and 7 days of treatment, along with an improvement in headache symptoms. [24]

Cineole has been shown to significantly reduce cough frequency, a clinically relevant parameter, thanks to its well-established anti-inflammatory and mucolytic properties. Acute bronchitis, which typically involves a persistent cough lasting more than five days and purulent sputum production in about half of patients, is primarily caused by viral pathogens such as influenza, parainfluenza, respiratory syncytial virus, coronavirus, adenovirus, and rhinovirus. Effective treatment should target the underlying pathophysiology and alleviate symptoms without causing significant side effects. Given its anti-inflammatory and bronchodilatory effects, cineole is considered a promising therapeutic option for acute bronchitis, fulfilling the criteria for a safe and effective treatment. [25]

**Potential Role of Eucalyptol (1,8-Cineole) in COVID-19 Management**

In the wake of the SARS-CoV-2 pandemic, researchers explored novel strategies to combat the virus. Among these approaches, attention was also directed toward the potential application of eucalyptol.

Computer modeling studies conducted by Sharma A.D. have explored the potential therapeutic applications of eucalyptol (1,8-cineole) in the context of COVID-19. [26]
In silico studies suggest that eucalyptol may inhibit the main protease (Mpro) of SARS-CoV-2, a critical enzyme involved in viral replication. Molecular docking analyses indicate that functional groups within the eucalyptol molecule, such as hydroxyl (-OH), ketone (=O), and ether (-O-) groups, can interact with key amino acids in the active site of Mpro, potentially blocking its activity. These findings highlight the potential of eucalyptol as a viral replication

inhibitor, though further in vitro and in vivo studies are needed to validate these computational results.

**Chronic Sinusitis**

Chronic sinusitis is characterized by persistent inflammation of the paranasal sinuses, often accompanied by nasal obstruction and impaired mucociliary clearance with symptoms lasting beyond 12 weeks and a prevalence of around 6% in Europe. [27] In addition to inflammation, the majority of CRS patients experience nasal obstruction and facial pressure, with nasal discharge and reduced sense of smell (hyposmia). Despite significant scientific advancements in understanding CRS, its exact etiology remains unclear. It is likely that CRS results from a combination of host-related factors and environmental influences as well as disturbance in microbiome composition inside the nasal cavity. [28] Current treatment for CRS typically involves managing symptoms with a combination of steroids, nasal irrigations, and antibiotics when purulence is present, alongside mucolytics, antihistamines, and leukotriene inhibitors to reduce inflammation, control infection, and support mucociliary clearance. [29] [30] [30]

Clinical trials have demonstrated that oral administration of 1,8-cineole significantly alleviates sinus symptoms and improves quality of life. In one randomized controlled trial, cineole reduced nasal congestion and improved endoscopic scores in patients with chronic rhinosinusitis. [29] The efficacy of 1,8-cineole in chronic sinusitis is attributed to its dual action: reducing inflammation and facilitating mucus clearance. These effects are supported by a systematic review highlighting its role in symptom management and quality of life improvements in patients resistant to conventional therapies.

The development of chronic rhinosinusitis (CRS) is frequently driven by bacterial infections, microbiome imbalances, or biofilm formation. It is well-established that Staphylococcus aureus is highly prevalent in the nasal cavities of CRS patients. [32] What is more, up to 80% of bacterial colonization in CRS presents as biofilms, whereas little to no biofilm formation is observed in healthy control groups. [33] This fact significantly reduces the effectiveness of conventional antibiotic treatments because bacteria are shielded from

antibiotics by the biofilm matrix, which is composed of various extracellular polymeric substances that render it impenetrable. [29] Essential oils, including 1,8-cineole, present an intriguing alternative to traditional antibiotics, as their molecules can penetrate the cell walls and membranes of prokaryotic cells and have been demonstrated to inhibit and eradicate S. aureus biofilms more effectively than traditional antibiotics. [34] Their primary mechanism of action involves disrupting layered polysaccharides and phospholipids, leading to membrane permeabilization. This results in the leakage of essential ions, such as potassium in Escherichia coli and S. aureus, a reduction in membrane potential, and the collapse of the proton pump, ultimately depleting the ATP pool. [35] [36] [37] Additionally, 1,8-cineole downregulates key biofilm-related genes, reduces inflammation by suppressing cytokine production, and restores mucosal health by modulating immune responses, emphasizing its potential as an effective treatment for biofilm-associated CRS. [34]

Additionally, approximately 25–30% of CRS patients develop nasal polyps, a condition referred to as CRSwNP. Nasal polyps are recognized as inflammatory lesions originating from the ethmoid sinus projecting into the nasal space and are more frequently observed in men. [38] The role of 1,8-cineole in reducing eosinophilic infiltration has been particularly emphasized in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). By targeting the IL-5-mediated inflammatory cascade, cineole not only alleviates symptoms but also delays polyp recurrence following surgical interventions. [39]

Nitric oxide (NO), known as a biological regulator in humans, plays roles as a vasodilator, bronchodilator, neurotransmitter, and inflammatory mediator in the lungs, with elevated levels observed in asthma and chronic rhinosinusitis (CRS) patients. [40] CRS patients exhibit high inducible NO synthase (iNOS) activity with increased exhaled NO but reduced nasal NO compared to controls, while nasal polyps show elevated endothelial NO synthase (eNOS) phosphorylation, contributing to inflammation and vascular permeability. [41] This dysregulation leads to edema and inflammation in conditions like CRSwNP (CRS with nasal polyps), highlighting the importance of NO in sinus inflammation. Furthermore, patients with allergic rhinitis exhibited elevated nasal NO levels, attributed to increased iNOS expression in nasal epithelial cells. [42] It was also demonstrated that eNOS phosphorylation is significantly higher in nasal polyps compared to inferior turbinates. The reduction of nasal NO through 1,8-cineole offers a promising phytotherapeutic alternative to glucocorticosteroids for airway diseases, particularly CRSwNP. [43]

**Asthma and Chronic obstructive pulmonary disease (COPD)**

Asthma, a chronic inflammatory condition of the airways, is associated with wheezing, shortness of breath, and airflow obstruction. Studies reveal that 1,8-cineole reduces airway inflammation and enhances pulmonary function.

Airway inflammation and mucociliary dysfunction in COPD and asthma patients have significant clinical consequences, including reduced lung function and exacerbation of symptoms. In COPD, smoking damages the ciliated epithelium and inflames the mucus membrane, impairing mucociliary transport and leading to mucus accumulation, which increases the risk of recurrent respiratory infections. Similarly, in asthma, chronic inflammation and mucus hypersecretion contribute to airway obstruction and reduced ciliary function. Cineole has been shown to enhance ciliary beat frequency, exert bronchodilating effects, and reduce inflammation. These properties suggest that cineole may positively impact exacerbations and lung function in both COPD and asthma, even when used as an adjunctive therapy. [7][44]

The double-blind trial of patients with stable COPD demonstrates that cineole significantly reduces the frequency, duration, and severity of exacerbations in patients compared to a placebo. During the treatment period, only 28.2% of patients in the cineole group experienced exacerbations, compared to 45.5% in the placebo group. Although the use of additional corticosteroids was not significantly different between groups, the results underscore the efficacy of cineole in managing exacerbations, suggesting its potential as an effective therapeutic option for reducing exacerbation burden. [44] The same findings highlight that cineole not only lowers exacerbation rates but also offers clinical advantages, including improved airflow, reduced dyspnea severity, and enhanced health status. As an adjunct to guideline-based treatments, cineole emerges as a valuable option for symptomatic COPD patients. Considering the high financial and social burden of COPD, cineole is particularly attractive due to its minimal side effects and low cost. The study provides strong evidence supporting the use of cineole as an additional therapeutic option, aligning with the results of efficacy studies on carbocysteine but contrasting with acetylcysteine, which failed to significantly reduce exacerbations. [44][45].

A comprehensive review examined the potential biological effects of 1,8-cineole on key therapeutic targets for chronic obstructive pulmonary disease (COPD) in animal models. [46] The study highlighted 1,8-cineole's interactions with crucial mediators in COPD's pathophysiological pathways, including receptors and membrane channels, oxidative stress, transcription factors, cytokine expression, cell adhesion molecules, neutrophil chemotaxis, pro-inflammatory cells, proteases, and tissue remodeling. The authors concluded that eucalyptol offers a significant complementary treatment option to traditional anti-inflammatory drugs for asthma and COPD.

The study made by Worth H. and Dethlefsen U. demonstrates that 1,8-cineole provides significant therapeutic benefits as an adjunctive treatment for asthma. Patients in the cineole group experienced a notable reduction in prednisolone use (36% vs. 7% in the placebo group), suggesting a prednisolone equivalent potency of 2.8 mg for 600 mg of cineole, which was well-tolerated. Additionally, cineole improved lung function, with a greater FEV1 increase (310 ml vs. 200 ml in the placebo group), and significantly enhanced scores for nightly asthma symptoms and the Asthma Quality of Life Questionnaire (AQLQ). [47] However, caution is necessary for asthmatics with severe perfume sensitivity, as cineole is exhaled and may cause irritation.

Previous randomized controlled trials evaluating exacerbation rates in COPD have demonstrated an additive effect of 1,8-cineole when combined with LABA + ICS therapies, showing a greater reduction in exacerbations compared to LABA + ICS alone. In the study, COPD patients were included with 80% receiving LABA and 23% on ICS, indicating a significant ICS-like effect of the multifunctional 1,8-cineole in real-world settings. This effect could potentially be even more pronounced in COPD patients treated with the current standard regimens of LAMA + LABA or LAMA + LABA + ICS. [47]

The bronchodilatory effects of 1,8-cineole have also been observed, mediated through its interaction with β2-adrenergic receptors, which relax bronchial smooth muscles.[48] This makes cineole particularly effective in addressing acute bronchospastic episodes and highlights its potential to complement existing COPD and asthma treatments.

## Future Directions

While existing research underscores the therapeutic potential of 1,8-cineole, several gaps remain. Future studies should explore its molecular mechanisms in greater detail, particularly its role in modulating immune cell activity. Additionally, the development of advanced delivery systems, such as inhalable formulations or sustained-release capsules, could enhance its bioavailability and therapeutic efficacy. The integration of 1,8-cineole into combination therapies also warrants investigation, particularly in the context of multidrug-resistant respiratory infections.

## Conclusion

1,8-Cineole is a natural therapeutic agent that is of promise against respiratory diseases, including chronic sinusitis, asthma, and upper respiratory tract infections. Indeed, due to its complex pathophysiology, the anti-inflammatory, mucolytic, bronchodilatory, antiviral, and antimicrobial activities of this compound show promising clinical evidence underlining its efficacy in symptom improvement, improvement in lung function, and enhancement of the quality of life, especially when administered as an adjunct to conventional treatment.

Besides, 1,8-cineole presents a very good safety profile and low side effects, making it an attractive alternative to traditional pharmacological approaches. Its potential to modulate key inflammatory pathways, inhibit biofilm formation, and enhance antiviral immunity further extends its scope of application, especially in the treatment of steroid-resistant and biofilm-associated conditions.

Although the current results are promising, further studies are still needed to confirm the efficacy and mechanisms of 1,8-cineole in various long-term respiratory diseases. Clinical trials should be further extended, and one of the most important strategies for enhancing its therapeutic benefit will be its synergistic use with other therapies. Conclusion: 1,8-cineole is a potent, multifunctional approach to respiratory health that meets the increasing demand for efficacious and well-tolerated natural therapies.

## Authors contributions

Conceptualization: Kamil Hermanowicz and Katarzyna Doman;
Methodology: Michał Jakub Cioch and Daria Oleksy
Check: Agnieszka Najdek and Dawid Komada

Formal analysis: Kamil Hermanowicz and Daria Oleksy

Investigation: Urszula Kaczmarska, Marcin Mycyk and Aleksandra Wożniak

Resources: Marcin Mycyk and Dawid Komada

Data curation: Kamil Hermanowicz

Writing – rough preparation: Michał Jakub Cioch

Writing - review and editing: Dawid Komada

Visualization: Julia Nowak and Urszula Kaczmarska

Supervision: Kamil Hermanowicz

Project administration: Kamil Hermanowicz

All authors have read and agreed with the published version of the manuscript.

**Funding Statement**

The study did not receive special funding.

**Institutional Review Board Statement**

Not applicable.

**Informed Consent Statement**

Not applicable.

**Data Availability Statement**

The data presented in this study is available upon request from the corresponding author.

**Acknowledgments**

Not applicable.

**Conflict of Interest Statement**

All authors declare that they have no conflicts of interest.

## REFERENCES

1. Zhao, C., Sun, J., Fang, C. & Tang, F. 1,8-cineol attenuates LPS-induced acute pulmonary inflammation in mice. Inflammation 37, 566–572. https://doi.org/10.1007/s10753-013-9770-4

2. Dhakad AK, Pandey VV, Beg S, Rawat JM, Singh A. Biological, medicinal and toxicological significance of eucalyptus leaf essential oil: a review. J Sci Food Agric. 2018;98:833–48. https://doi.org/10.1002/jsfa.8600

3. Nakamura T, Yoshida N, Yamanoi Y, Honryo A, Tomita H, Kuwabara H, Kojima Y. Eucalyptus oil reduces allergic reactions and suppresses mast cell degranulation by downregulating IgE-FcεRI signalling. Sci Rep. 2020 Dec 1;10(1):20940. PMID: 33262354; PMCID: PMC7708995. https://doi.org/10.1038/s41598-020-77039-5

4. Juergens UR, Stöber M, Schmidt-Schilling L, Kleuver T, Vetter H. Antiinflammatory effects of euclyptol (1.8-cineole) in bronchial asthma: inhibition of arachidonic acid metabolism in human blood monocytes ex vivo. Eur J Med Res. 1998 Sep 17;3(9):407-12. PMID: 9737886.

5. Juergens UR, Stöber M, Vetter H. Inhibition of cytokine production and arachidonic acid metabolism by eucalyptol (1.8-cineole) in human blood monocytes in vitro. Eur J Med Res. 1998 Nov 17;3(11):508-10. PMID: 9810029.

6. Juergens LJ, Worth H, Juergens UR. New Perspectives for Mucolytic, Anti-inflammatory and Adjunctive Therapy with 1,8-Cineole in COPD and Asthma: Review on the New Therapeutic Approach. Adv Ther. 2020 May;37(5):1737-1753. Epub 2020 Mar 21. PMID: 32200535; PMCID: PMC7467491. https://doi.org/10.1007/s12325-020-01279-0

7. Sudhoff H, Klenke C, Greiner JF, et al. 1,8-Cineole reduces mucus-production in a novel human ex vivo model of late rhinosinusitis. PLoS One. 2015;10(7):e0133040. https://doi.org/10.1371/journal.pone.0133040

8. Hyun-Seung Lee,a Da-Eun Park,b Woo-Jung Song,b Heung-Woo Park,b Hye-Ryun Kang,b Sang-Heon Cho,b and Seong-Wook Sohn. Effect of 1.8-Cineole in Dermatophagoides pteronyssinus-Stimulated Bronchial Epithelial Cells and Mouse Model of Asthma; https://doi.org/10.1248/bpb.b15-00876

9.Müller J, Greiner JF, Zeuner M, Brotzmann V, Schäfermann J, Wieters F, Widera D, Sudhoff H, Kaltschmidt B, Kaltschmidt C. 1,8-Cineole potentiates IRF3-mediated antiviral response in human stem cells and in an ex vivo model of rhinosinusitis. Clin Sci (Lond). 2016 Aug 1;130(15):1339-52. Epub 2016 Apr 25. PMID: 27129189. https://doi.org/10.1042/CS20160218

10. Müller, J., Greiner, J. F. W., Zeuner, M., Brotzmann, V., Schäfermann, J., Wieters, F., Widera, D. ORCID: https://orcid.org/0000-0003-1686-130X, Sudhoff, H., Kaltschmidt, B. and Kaltschmidt, C. (2016) 1,8-cineol potentiates IRF3-mediated antiviral response in human stem cells and an ex vivo model of rhinosinusitis. Clinical Science. ISSN 0143-5221 doi: https://doi.org/10.1042/CS20160218

11. Gwaltney JM Jr. Rhinovirus infection of the normal human airway. Am J Respir Crit Care Med. 1995 Oct;152(4 Pt 2):S36-9. doi: 10.1164/ajrccm/152.4_Pt_2.S36. PMID: 7551410. https://doi.org/10.1164/ajrccm/152.4_Pt_2.S36

12. Greiner JF, Müller J, Zeuner MT, Hauser S, Seidel T, Klenke C, Grunwald LM, Schomann T, Widera D, Sudhoff H, Kaltschmidt B, Kaltschmidt C. 1,8-Cineol inhibits

nuclear translocation of NF-κB p65 and NF-κB-dependent transcriptional activity. Biochim Biophys Acta. 2013 Dec;1833(12):2866-2878. Epub 2013 Jul 18. PMID: 23872422. https://doi.org/10.1016/j.bbamcr.2013.07.001

13. Astani A, Reichling J, Schnitzler P. Comparative study on the antiviral activity of selected monoterpenes derived from essential oils. Phytother Res. 2010 May;24(5):673-9. PMID: 19653195; PMCID: PMC7167768. https://doi.org/10.1002/ptr.2955

14. Fyfe L, Armstrong F, Stewart J. Inhibition of Listeria monocytogenes and Salmonella enteriditis by combinations of plant oils and derivatives of benzoic acid: The development of synergistic antimicrobial combinations. Int J Antimicrob Agents. 1997;9:195–9. https://doi.org/10.1016/s0924-8579(97)00051-4

15. Filoche SK, Soma K, Sissons CH. Antimicrobial effects of essential oils in combination with chlorhexidine digluconate. Oral Microbiol Immunol. 2005;20:221–5. https://doi.org/10.1111/j.1399-302X.2005.00216.x

16. Cowan MM. Plant products as antimicrobial agents. Clin Microbiol Rev. 1999;12:564–82. doi: 10.1128/cmr.12.4.564.

17. Merih Şimşek, Reşat Duman; Investigation of Effect of 1,8-cineole on Antimicrobial Activity of Chlorhexidine Gluconate; 2017 Jul-Sep;9(3):234–237. https://doi.org/10.4103/0974-8490.210329

18. Addo K.A., Li L., Li H., Yu Y., Xiao X. Osmotic stress relief antibiotic tolerance of 1,8-cineole in biofilm persister cells of Escherichia coli O157:H7 and expression of toxin-antitoxin system genes. Microb. Pathog. 2022;173:105883. https://doi.org/10.1016/j.micpath.2022.105883

19. Landeo-Villanueva G.E., Salazar-Salvatierra M.E., Ruiz-Quiroz J.R., Zuta-Arriola N., Jarama-Soto B., Herrera-Calderon O., Pari-Olarte J.B., Loyola-Gonzales E. Inhibitory Activity of Essential Oils of Mentha spicata and Eucalyptus globulus on Biofilms of Streptococcus mutans in an In Vitro Model. Antibiotics. 2023;12:369. https://doi.org/10.3390/antibiotics12020369

20. Hall, C. W., and Mah, T. F. (2017). Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria. FEMS Microbiol. Rev. 41, 276–301. https://doi.org/10.1093/femsre/fux010

21. Worth H., Schacher C., Dethlefsen U. Concomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: A placebo-controlled double-blind trial. Respir. Res. 2009;10:69. https://doi.org/10.1186/1465-9921-10-69

22. Api A.M., Belsito D., Botelho D., Bruze M., Burton G.A., Cancellieri M.A., Chon H., Dagli M.L., Date M., Dekant W., et al. RIFM fragrance ingredient safety assessment, gamma-hexalactone, CAS Registry Number 695-06-7. Food Chem. Toxicol. 2022;167:113278. https://doi.org/10.1016/j.fct.2022.113278

23. Cai Z.M., Peng J.Q., Chen Y., Tao L., Zhang Y.Y., Fu L.Y., Long Q.D., Shen X.C. 1,8-Cineole: A review of source, biological activities, and application. J. Asian Nat. Prod. Res. 2021;23:938–954. https://doi.org/10.1080/10286020.2020.1839432

24. Kehrl W, Sonnemann U, Dethlefsen U. Therapy for acute nonpurulent rhinosinusitis with cineole: results of a double-blind, randomized, placebo-controlled trial. Laryngoscope. 2004 Apr;114(4):738-42. PMID: 15064633. https://doi.org/10.1097/00005537-200404000-00027

25. Fischer J, Dethlefsen U. Efficacy of cineole in patients suffering from acute bronchitis: a placebo-controlled double-blind trial. Cough. 2013 Nov 21;9(1):25. PMID: 24261680; PMCID: PMC3842692, https://doi.org/10.1186/1745-9974-9-25

26. Sharma AD, Eucalyptol (1,8 cineole) from Eucalyptus Essential Oil a Potential Inhibitor of COVID 19 Corona Virus Infection by Molecular Docking Studies, https://doi.org/10.20944/preprints202003.0455.v1

27. Hastan, D., Fokkens, W. J., Bachert, C., Newson, R. B., Bislimovska, J., Bockelbrink, A., et al. (2011). Chronic rhinosinusitis in Europe–an underestimated disease. A GA(2)LEN study. Allergy 66, 1216–1223. https://doi.org/10.1111/j.1398-9995.2011.02646.x

28. Kennedy, D. W. (2004). Pathogenesis of chronic rhinosinusitis. Ann. Otol. Rhinol. Laryngol. 113, 6–9. https://doi.org/10.1177/00034894041130s503

29. Joe, S. A., Thambi, R., and Huang, J. (2008). A systematic review of the use of intranasal steroids in the treatment of chronic rhinosinusitis. Otolaryngol. Head Neck Surg. 139, 340–347. https://doi.org/10.1016/j.otohns.2008.05.628

30 Bachmann, G., Hommel, G., and Michel, O. (2000). Effect of irrigation of the nose with isotonic salt solution on adult patients with chronic paranasal sinus disease. Eur. Arch. Otorhinolaryngol. 257, 537–541. https://doi.org/10.1007/s004050000271

31. Suh, J. D., and Kennedy, D. W. (2011). Treatment options for chronic rhinosinusitis. Proc. Am. Thorac. Soc. 8, 132–140. https://doi.org/10.1513/pats.201003-028RN

32. Feazel, L. M., Robertson, C. E., Ramakrishnan, V. R., and Frank, D. N. (2012). Microbiome complexity and Staphylococcus aureus in chronic rhinosinusitis. Laryngoscope 122, 467–472. https://doi.org/10.1002/lary.22398

33. Singh, P., Mehta, R., Agarwal, S., and Mishra, P. (2015). Bacterial biofilm on the sinus mucosa of healthy subjects and patients with chronic rhinosinusitis (with or without nasal polyposis). J. Laryngol. Otol. 129, 46–49. https://doi.org/10.1017/S002221511400303X

34. M. Schürmann ,F. Oppel1 ,M. Gottschalk ,B. Büker ,C. A. Jantos ,C. Knabbe ,A. Hütten ,B. Kaltschmidt ,C. Kaltschmidt and H. Sudhoff ;The Therapeutic Effect of 1,8-Cineol on Pathogenic Bacteria Species Present in Chronic Rhinosinusitis; 2019, https://doi.org/10.3389/fmicb.2019.02325

35. Swamy, M. K., Akhtar, M. S., and Sinniah, U. R. (2016). Antimicrobial properties of plant essential oils against human pathogens and their mode of action: an updated review. Evid. Based Complement. Alternat. Med. 2016:3012462. https://doi.org/10.1155/2016/3012462

36. Bakkali F, Averbeck S, Averbeck D, Idaomar M. Biological effects of essential oils--a review. Food Chem Toxicol. 2008 Feb;46(2):446-75. Epub 2007 Sep 29. PMID: 17996351. https://doi.org/10.1016/j.fct.2007.09.106

37. Kavanaugh, N. L., and Ribbeck, K. (2012). Selected antimicrobial essential oils eradicate Pseudomonas spp. and Staphylococcus aureus biofilms. Appl. Environ. Microbiol. 78, 4057–4061. https://doi.org/10.1128/AEM.07499-11

38. Stevens, W. W., Schleimer, R. P., and Kern, R. C. (2016). Chronic rhinosinusitis with nasal polyps. J. Allergy Clin. Immunol. Pract. 4, 565–572. https://doi.org/10.1016/j.jaip.2016.04.012

39. Junqin Bai, Julia H. Huang, Caroline P.E. Price, Atsushi Kato, Robert P. Schleimer, Bruce K. Tan; Prognostic factors for polyp recurrence in chronic rhinosinusitis with nasal polyps; https://doi.org/10.1016/j.jaci.2022.02.029

40. Sahin, G., et al., Nitric oxide: a promising methodological approach in airway diseases. Int 423 Arch Allergy Immunol, 2011. 156(4): p. 352-61; https://doi.org/10.1159/000324678.

41. Gilain L, Bedu M, Jouaville L, Guichard C, Advenier D, Mom T, Laurent S, Caillaud D. Analyse des concentrations nasales et dans l'air expiré du monoxyde d'azote (NO) dans la polypose naso-sinusienne [Analysis of nasal and exhaled nitric oxide concentration in nasal polyposis]. Ann Otolaryngol Chir Cervicofac. 2002 Sep;119(4):234-42. French. PMID: 12410120

42. Serrano, C., A. Valero, and C. Picado, [Nasal nitric oxide]. Arch Bronconeumol, 2004. 40(5): p. 427 222-30. https://doi.org/10.1016/s1579-2129(06)70088-x

43. M. Koennecke, F. Benecke, A. Masche, R. Linke, K.-L. Bruchhage, R. Pries, L. Klimek, B. Wollenberg; https://doi.org/10.1016/j.niox.2018.06.002

44. Juergens UR, Dethlefsen U, Steinkamp A, Gillissen A, Repges R, Vetter H: Anti-inflammatory activity of 1.8-Cineole (Eucalyptol) in bronchial asthma: a double-blind placebo controlled trial. Respiratory Medicine 2003, 97:250-256.; https://doi.org/10.1053/rmed.2003.1432

45. Zheng JP, Kang J, Huang SG, Chen P, Yao WZ, Yang L, Bai CX, Wang CZ, Wang C, Chen BY, Shi Y, Liu CT, Chen P, Li Q, Wang ZS, Huang YJ, Luo ZY, Chen FP, Yuan JZ, Yuan BT, Qian HP, Zhi RC, Zhong NS: Effect of Carbocysteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet 2008, 371:2013-2018; https://doi.org/10.1016/S0140-6736(08)60869-7

46. De Lima Gondim F, dos Santos GR, do Nascimento IFMG, Serra DS, Cavalcante FSA. Beneficial effects of eucalyptol in the pathophysiological changes of the respiratory system: a proposal for alternative pharmacological therapy for individuals with COPD. Eur J Med Plants. 2018;25(1):1–10; https://doi.org/10.9734/EJMP/2018/43561

47. Worth H, Dethlefsen U. Patients with asthma benefit from concomitant therapy with cineole: a placebo-controlled, double-blind trial. J Asthma. 2012;49(8):849–53. https://doi.org/10.3109/02770903.2012.717657

48. Bastos VP, Brito TS, Lima FJ. Inhibitory effect of 1,8 cineole on guinea-pig airway challenged with ovalbumin involves a preferential action on electromechanical coupling. Clin Exp Pharmacol Physiol. 2009;36(11):1120–6. https://doi.org/10.1111/j.1440-1681.2009.05189.x